Is Tumor Mutation Burden a predictive Marker for AJCC Stage II Melanoma?

被引：0
|
作者：
Sinnberg, T. [1 ]
Niessner, H. [1 ]
Amaral, T. [1 ,2 ]
Eigentler, T. [1 ]
Schroeder, C. [3 ]
Lindner, E. S. [3 ]
Hilke, F. J. [3 ,4 ]
Bonzheim, I. [5 ]
Fend, F. [5 ]
Riess, O. [3 ]
Garbe, C. [1 ]
机构：
[1] Univ Hautklin Tubingen, Zentrum Dermatoonkol, Tubingen, Germany
[2] Portuguese Air Force, Hlth Care Direct, Lisbon, Portugal
[3] Univ Klinikum Tubingen, Inst Med Genet & Angew Genom, Tubingen, Germany
[4] Charite Univ Med Berlin, Dermatol, Berlin, Germany
[5] Univ Klinikum Tubingen, Inst Pathol, Tubingen, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2020年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV34
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [1] Is tumor mutational burden a prognostic marker in AJCC stage II melanoma?
    Amaral, Teresa
    Sinnberg, Tobias
    Schroeder, Christopher
    Linder, Elena Sofia
    Niessner, Heike
    Bonzheim, Irina
    Eigentler, Thomas
    Fend, Falko
    Riess, Olaf
    Garbe, Claus
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18
  • [2] Is tumor mutational burden a prognostic marker in AJCC stage II melanoma?
    Sinnberg, T.
    Niessner, H.
    Amaral, T.
    Eigentler, T.
    Schroeder, C.
    Lindner, E. S.
    Hilke, F. J.
    Bonzheim, I.
    Fend, F.
    Riess, O.
    Garbe, C.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 (03) : E29 - E29
  • [3] Is tumor mutational burden a prognostic marker in AJCC stage II melanoma?
    Sinnberg, T.
    Niessner, H.
    Amaral, T.
    Eigentler, T.
    Schroeder, C.
    Lindner, E. S.
    Hilke, F. J.
    Bonzheim, I.
    Fend, F.
    Riess, O.
    Garbe, C.
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (04) : E34 - E34
  • [4] Is the Tumor Burden in the Sentinel Lymph Node prognostically significant in AJCC 2017 Stage III Melanoma Patients?
    Satzger, I.
    Leiter-Stoeppke, U.
    Graeger, N.
    Keim, U.
    Garbe, C.
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 15 - 16
  • [5] Melanoma cefl expression of macrophage markers in AJCC stage I/II melanoma
    Jensen, T. O.
    Schmidt, H.
    Steiniche, T.
    Hoyer, M.
    Moller, H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] The prognostic role of macrophages in AJCC stage I/II melanoma
    Jensen, Trine O.
    Schmidt, Henrik
    Moeller, Holger Jon
    Hoeyer, Morten
    Sjoegren, Pia
    Steiniche, Torben
    APMIS, 2008, 116 (03) : 242 - 243
  • [7] The prognostic role of protumoral macrophages in AJCC stage I/II melanoma
    Jensen, T. O.
    Hoyer, M.
    Schmidt, H.
    Moller, H. J.
    Steiniche, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] AJCC nodal factors and microscopic tumor burden predict recurrence in sentinel lymph node positive stage III melanoma patients
    Andtbacka, RH
    Bedrosian, I
    Ross, MJ
    Lin, E
    Prieto, VG
    Aloia, TA
    Cormier, JN
    Lee, JE
    Mansfield, PF
    Gershenwald, JE
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 12 - 12
  • [9] Tumor Budding as a Predictive Marker of Relapse and Survival in Patients With Stage II Colon Cancer
    Saito, Kazuyuki
    Okuyama, Takashi
    Miyazaki, Shunya
    Oi, Haruka
    Mitsui, Takashi
    Noro, Takuji
    Takeshita, Emiko
    Ono, Yuko
    Urahashi, Taizen
    Tajima, Hidehiro
    Yoshitomi, Hideyuki
    IN VIVO, 2022, 36 (04): : 1820 - 1828
  • [10] Age and gender influence the progression of AJCC Stage I/II melanoma.
    Mcelrath-Garza, A
    Wanek, L
    Morton, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 713S - 713S
12345